Clin2
NCT07263425Possibly a fitRecruiting

Study of thiotepa and trastuzumab for breast cancer that spread to the lining of the brain and spinal cord

Leptomeningeal Metastasis of HER2-positive Breast Cancer

Part of Brain & nervous system, Cancer clinical trials.

This trial tests a combination of two drugs given through a special port in the head to treat HER2-positive breast cancer that has spread to the layer covering the brain and spinal cord (leptomeningeal metastasis). It aims to see if this treatment is safe and effective.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
26 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have HER2-positive breast cancer, confirmed by a biopsy or other lab tests
  • You have been diagnosed with leptomeningeal metastasis (cancer spread to the lining of the brain and spinal cord)
  • You already have or are able to get a small device called an Ommaya reservoir placed in your head to deliver the drugs
  • You are between 18 and 75 years old
  • Your overall health, blood counts, and organ function are good enough for treatment
  • You are not pregnant, not breastfeeding, and willing to avoid pregnancy during the study and for 6 months after

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06543992Recruiting· Phase 2
Chemotherapy for breast cancer that spread to the brain lining

This trial tests a combination of two chemotherapy drugs (thiotepa and methotrexate) given directly into the fluid around your brain and spine through a small implanted device. It aims to treat breast cancer that has spread to the lining of the brain or spinal cord.

Nanjing, Jiangsu
NCT07744529Recruiting· Phase 1/Phase 2
Combination treatment for lung cancer spread to the lining of the brain

This trial tests a new combination of two drugs for people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord. The treatment aims to target the cancer cells and may help improve symptoms and survival.

Hangzhou, Zhejiang
NCT07751536Recruiting
Proton radiation and intrathecal chemo for lung cancer that has spread to the brain lining

This trial tests a combination of proton radiation to the brain and spine plus chemotherapy given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and has continued to grow despite taking a third-generation TKI medicine like osimertinib.

Hefei, Anhui
NCT07511725Recruiting· Phase 2
Thiotepa spinal injection to prevent glioblastoma spread

This trial tests whether injecting a chemotherapy drug called thiotepa into the fluid around the brain and spine can prevent glioblastoma from spreading in patients whose tumor touches the fluid-filled spaces or who had a leak during surgery.

Hangzhou, Zhejiang
NCT06230055Recruiting· Phase 4
Chemotherapy for breast cancer that has spread to the spinal fluid

This trial tests a chemotherapy drug given directly into the spinal fluid for people with HER2-negative breast cancer that has spread to the lining of the brain and spinal cord (called leptomeningeal metastasis). It may help when standard treatments have stopped working or caused too many side effects.

Shanghai, Shanghai Municipality
NCT07778940Not yet recruiting· Phase 2
Chemotherapy through a brain port for lung cancer that has spread to the spinal fluid

This trial tests a chemotherapy drug called thiotepa, given through a small device placed under the scalp (Ommaya reservoir) that delivers the drug directly into the spinal fluid. It is for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord and who have stopped responding to certain targeted therapies.

Tianjin

Hear when a new Leptomeningeal Metastasis of HER2-positive Breast Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.